BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Misiak B, Stańczykiewicz B, Kotowicz K, Rybakowski JK, Samochowiec J, Frydecka D. Cytokines and C-reactive protein alterations with respect to cognitive impairment in schizophrenia and bipolar disorder: A systematic review. Schizophr Res 2018;192:16-29. [PMID: 28416092 DOI: 10.1016/j.schres.2017.04.015] [Cited by in Crossref: 79] [Cited by in F6Publishing: 75] [Article Influence: 15.8] [Reference Citation Analysis]
Number Citing Articles
1 Orsolini L, Sarchione F, Vellante F, Fornaro M, Matarazzo I, Martinotti G, Valchera A, Di Nicola M, Carano A, Di Giannantonio M, Perna G, Olivieri L, De Berardis D. Protein-C Reactive as Biomarker Predictor of Schizophrenia Phases of Illness? A Systematic Review. Curr Neuropharmacol 2018;16:583-606. [PMID: 29357805 DOI: 10.2174/1570159X16666180119144538] [Cited by in Crossref: 25] [Cited by in F6Publishing: 15] [Article Influence: 6.3] [Reference Citation Analysis]
2 Klaus F, Mitchell K, Liou SC, Eyler LT, Nguyen TT. Chemokine MCP1 is associated with cognitive flexibility in schizophrenia: A preliminary analysis. J Psychiatr Res 2021;138:139-45. [PMID: 33852994 DOI: 10.1016/j.jpsychires.2021.04.007] [Reference Citation Analysis]
3 Zhou R, Xu J, Luan J, Wang W, Tang X, Huang Y, Su Z, Yang L, Gu Z. Predictive role of C-reactive protein in sudden death: a meta-analysis of prospective studies. J Int Med Res 2022;50:3000605221079547. [PMID: 35225715 DOI: 10.1177/03000605221079547] [Reference Citation Analysis]
4 Stamatovich SN, Lopez-gamundi P, Suchting R, Colpo GD, Walss-bass C, Lane SD, Schmitz JM, Wardle MC. Plasma pro- and anti-inflammatory cytokines may relate to cocaine use, cognitive functioning, and depressive symptoms in cocaine use disorder. The American Journal of Drug and Alcohol Abuse 2021;47:52-64. [DOI: 10.1080/00952990.2020.1828439] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
5 Pogocki D, Kisała J, Cebulski J. Depression as is Seen by Molecular Spectroscopy. Phospholipid- Protein Balance in Affective Disorders and Dementia. Curr Mol Med 2020;20:484-7. [PMID: 31854279 DOI: 10.2174/1566524020666191219102746] [Reference Citation Analysis]
6 Zhu S, Zhao L, Fan Y, Lv Q, Wu K, Lang X, Li Z, Yi Z, Geng D. Interaction between TNF-α and oxidative stress status in first-episode drug-naïve schizophrenia. Psychoneuroendocrinology 2020;114:104595. [DOI: 10.1016/j.psyneuen.2020.104595] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 7.0] [Reference Citation Analysis]
7 Michalczyk A, Tyburski E, Podwalski P, Waszczuk K, Rudkowski K, Kucharska-mazur J, Mak M, Rek-owodziń K, Plichta P, Bielecki M, Andrusewicz W, Cecerska-heryć E, Samochowiec A, Misiak B, Sagan L, Samochowiec J. Serum inflammatory markers and their associations with white matter integrity of the corpus callosum in schizophrenia patients and healthy controls. Progress in Neuro-Psychopharmacology and Biological Psychiatry 2022. [DOI: 10.1016/j.pnpbp.2022.110510] [Reference Citation Analysis]
8 Jin Y, Sun LH, Yang W, Cui RJ, Xu SB. The Role of BDNF in the Neuroimmune Axis Regulation of Mood Disorders. Front Neurol 2019;10:515. [PMID: 31231295 DOI: 10.3389/fneur.2019.00515] [Cited by in Crossref: 46] [Cited by in F6Publishing: 44] [Article Influence: 15.3] [Reference Citation Analysis]
9 Misiak B, Ricceri L, Sąsiadek MM. Transposable Elements and Their Epigenetic Regulation in Mental Disorders: Current Evidence in the Field. Front Genet 2019;10:580. [PMID: 31293617 DOI: 10.3389/fgene.2019.00580] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 7.3] [Reference Citation Analysis]
10 Pranckeviciene A, Deltuva VP, Tamasauskas A, Zegliene J, Bunevicius A. Clinical and Biological Correlates of Preoperative Cognitive Functioning of Glioma and Meningioma Patients. Biomed Res Int 2020;2020:2054859. [PMID: 32461966 DOI: 10.1155/2020/2054859] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
11 Momtazmanesh S, Zare-Shahabadi A, Rezaei N. Cytokine Alterations in Schizophrenia: An Updated Review. Front Psychiatry 2019;10:892. [PMID: 31908647 DOI: 10.3389/fpsyt.2019.00892] [Cited by in Crossref: 49] [Cited by in F6Publishing: 48] [Article Influence: 16.3] [Reference Citation Analysis]
12 Habtewold TD, Rodijk LH, Liemburg EJ, Sidorenkov G, Boezen HM, Bruggeman R, Alizadeh BZ. A systematic review and narrative synthesis of data-driven studies in schizophrenia symptoms and cognitive deficits. Transl Psychiatry 2020;10:244. [PMID: 32694510 DOI: 10.1038/s41398-020-00919-x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 9.5] [Reference Citation Analysis]
13 Prestwood TR, Asgariroozbehani R, Wu S, Agarwal SM, Logan RW, Ballon JS, Hahn MK, Freyberg Z. Roles of inflammation in intrinsic pathophysiology and antipsychotic drug-induced metabolic disturbances of schizophrenia. Behav Brain Res 2021;402:113101. [PMID: 33453341 DOI: 10.1016/j.bbr.2020.113101] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
14 Garés-caballer M, Sánchez-ortí JV, Correa-ghisays P, Balanzá-martínez V, Selva-vera G, Vila-francés J, Magdalena-benedito R, San-martin C, Victor VM, Escribano-lopez I, Hernandez-mijares A, Vivas-lalinde J, Vieta E, Leza JC, Tabarés-seisdedos R. Immune–Inflammatory Biomarkers Predict Cognition and Social Functioning in Patients With Type 2 Diabetes Mellitus, Major Depressive Disorder, Bipolar Disorder, and Schizophrenia: A 1-Year Follow-Up Study. Front Neurol 2022;13:883927. [DOI: 10.3389/fneur.2022.883927] [Reference Citation Analysis]
15 Fathian F, Løberg EM, Gjestad R, Steen VM, Kroken RA, Jørgensen HA, Johnsen E. Associations between C-reactive protein levels and cognition during the first 6 months after acute psychosis. Acta Neuropsychiatr 2019;31:36-45. [PMID: 30394240 DOI: 10.1017/neu.2018.25] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
16 Karagüzel EÖ, Arslan FC, Uysal EK, Demir S, Aykut DS, Tat M, Karahan SC. Blood levels of interleukin-1 beta, interleukin-6 and tumor necrosis factor-alpha and cognitive functions in patients with obsessive compulsive disorder. Compr Psychiatry 2019;89:61-6. [PMID: 30594753 DOI: 10.1016/j.comppsych.2018.11.013] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
17 Fahey L, Donohoe G, Broin PÓ, Morris DW. Genes regulated by BCL11B during T-cell development are enriched for de novo mutations found in schizophrenia patients. Am J Med Genet B Neuropsychiatr Genet 2020;183:370-9. [PMID: 32729240 DOI: 10.1002/ajmg.b.32811] [Reference Citation Analysis]
18 Duan F, Zhao S, Xia C, Ren Z, Yuan N, Xie L, Wang L, Xiong Y, Yu P, Chen Y, Tian J, Dai J, Lu J, Xia Y, Liu X, Chen C, Liu C. Changes of immune-related factors in the blood of schizophrenia and bipolar disorder patients receiving monotherapy. Transl Psychiatry 2022;12:212. [PMID: 35618730 DOI: 10.1038/s41398-022-01968-0] [Reference Citation Analysis]
19 Dash S, Syed YA, Khan MR. Understanding the Role of the Gut Microbiome in Brain Development and Its Association With Neurodevelopmental Psychiatric Disorders. Front Cell Dev Biol 2022;10:880544. [DOI: 10.3389/fcell.2022.880544] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
20 Miller BJ, Goldsmith DR. Inflammatory biomarkers in schizophrenia: Implications for heterogeneity and neurobiology. Biomarkers in Neuropsychiatry 2019;1:100006. [DOI: 10.1016/j.bionps.2019.100006] [Cited by in Crossref: 12] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
21 Kessing LV, Miskowiak K. Does Cognitive Dysfunction in Bipolar Disorder Qualify as a Diagnostic Intermediate Phenotype?-A Perspective Paper. Front Psychiatry 2018;9:490. [PMID: 30349492 DOI: 10.3389/fpsyt.2018.00490] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
22 Boozalis T, Teixeira AL, Cho RY, Okusaga O. C-Reactive Protein Correlates with Negative Symptoms in Patients with Schizophrenia. Front Public Health 2017;5:360. [PMID: 29404313 DOI: 10.3389/fpubh.2017.00360] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
23 Misiak B, Bartoli F, Carrà G, Małecka M, Samochowiec J, Jarosz K, Banik A, Stańczykiewicz B. Chemokine alterations in bipolar disorder: A systematic review and meta-analysis. Brain, Behavior, and Immunity 2020;88:870-7. [DOI: 10.1016/j.bbi.2020.04.013] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 7.0] [Reference Citation Analysis]
24 Wu ZW, Yu HH, Wang X, Guan HY, Xiu MH, Zhang XY. Interrelationships Between Oxidative Stress, Cytokines, and Psychotic Symptoms and Executive Functions in Patients With Chronic Schizophrenia. Psychosom Med 2021;83:485-91. [PMID: 34080586 DOI: 10.1097/PSY.0000000000000931] [Reference Citation Analysis]
25 Tan BL, Norhaizan ME. Effect of High-Fat Diets on Oxidative Stress, Cellular Inflammatory Response and Cognitive Function. Nutrients 2019;11:E2579. [PMID: 31731503 DOI: 10.3390/nu11112579] [Cited by in Crossref: 39] [Cited by in F6Publishing: 40] [Article Influence: 13.0] [Reference Citation Analysis]
26 Qiu Y, Li S, Teng Z, Tan Y, Xu X, Yang M, Zhao Z, Liu J, Tang H, Xiang H, Chen J, Wang B, Wu H. Association between abnormal glycolipid level and cognitive dysfunction in drug-naïve patients with bipolar disorder. J Affect Disord 2022;297:477-85. [PMID: 34715186 DOI: 10.1016/j.jad.2021.10.100] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
27 Chauhan P, Kaur G, Prasad R, Singh H. Pharmacotherapy of schizophrenia: immunological aspects and potential role of immunotherapy. Expert Rev Neurother 2021;:1-13. [PMID: 34654348 DOI: 10.1080/14737175.2021.1994857] [Reference Citation Analysis]
28 Melo MCA, Garcia RF, de Araújo CFC, Abreu RLC, de Bruin PFC, de Bruin VMS. Clinical significance of neutrophil-lymphocyte and platelet-lymphocyte ratios in bipolar patients: An 18-month prospective study. Psychiatry Research 2019;271:8-14. [DOI: 10.1016/j.psychres.2018.10.077] [Cited by in Crossref: 17] [Cited by in F6Publishing: 10] [Article Influence: 5.7] [Reference Citation Analysis]
29 Yakimets AV, Zozulya SA, Oleichik IV, Klyushnik TP. [Dynamics of clinical and biological indices of the asthenic symptom-complex during immunotropic therapy of patients with schizophrenia]. Zh Nevrol Psikhiatr Im S S Korsakova 2018;118:70-6. [PMID: 29652309 DOI: 10.17116/jnevro20181183170-76] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
30 Miller BJ, Pikalov A, Siu CO, Tocco M, Tsai J, Harvey PD, Newcomer JW, Loebel A. Association of C-reactive protein and metabolic risk with cognitive effects of lurasidone in patients with schizophrenia. Compr Psychiatry 2020;102:152195. [PMID: 32896775 DOI: 10.1016/j.comppsych.2020.152195] [Reference Citation Analysis]
31 Pan LH, Qian M, Qu W, Tang Q, Yan Y. Serum C-Reactive Protein in Patients with Deficit Schizophrenia and the Relationship with Cognitive Function. Neuropsychiatr Dis Treat 2020;16:2891-7. [PMID: 33293814 DOI: 10.2147/NDT.S284149] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
32 George RP, Semendric I, Hutchinson MR, Whittaker AL. Neuroimmune reactivity marker expression in rodent models of chemotherapy-induced cognitive impairment: A systematic scoping review. Brain Behav Immun 2021;94:392-409. [PMID: 33516919 DOI: 10.1016/j.bbi.2021.01.021] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
33 Xiu MH, Man LJ, Wang D, Du X, Yin G, Zhang Y, Tan YL, Chen N, Chen S, Teixeira AL, Cassidy RM, Soares JC, Zhang XY. Tumor necrosis factor-alpha -1031T/C polymorphism is associated with cognitive deficits in chronic schizophrenia patients versus healthy controls. Am J Med Genet B Neuropsychiatr Genet 2018;177:379-87. [PMID: 29633506 DOI: 10.1002/ajmg.b.32622] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
34 Imai R, Hori H, Itoh M, Lin M, Niwa M, Ino K, Ogawa S, Ishida M, Sekiguchi A, Matsui M, Kunugi H, Akechi T, Kamo T, Kim Y. Inflammatory markers and their possible effects on cognitive function in women with posttraumatic stress disorder. J Psychiatr Res 2018;102:192-200. [PMID: 29684628 DOI: 10.1016/j.jpsychires.2018.04.009] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 5.3] [Reference Citation Analysis]
35 Mak M, Samochowiec J, Frydecka D, Pełka-wysiecka J, Szmida E, Karpiński P, Sąsiadek MM, Piotrowski P, Samochowiec A, Misiak B. First-episode schizophrenia is associated with a reduction of HERV-K methylation in peripheral blood. Psychiatry Research 2019;271:459-63. [DOI: 10.1016/j.psychres.2018.12.012] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
36 Popiołek AK, Chyrek-Tomaszewska A, Stachowicz-Karpińska A, Bieliński MK, Borkowska A. Biochemical Parameters in Cognitive Functions. Neuropsychiatr Dis Treat 2020;16:2479-89. [PMID: 33149589 DOI: 10.2147/NDT.S267673] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
37 Gómez-Rubio P, Trapero I. The Effects of Exercise on IL-6 Levels and Cognitive Performance in Patients with Schizophrenia. Diseases 2019;7:E11. [PMID: 30678202 DOI: 10.3390/diseases7010011] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
38 González-Blanco L, García-Portilla MP, García-Álvarez L, de la Fuente-Tomás L, Iglesias García C, Sáiz PA, Rodríguez-González S, Coto-Montes A, Bobes J. Can interleukin-2 and interleukin-1β be specific biomarkers of negative symptoms in schizophrenia? Rev Psiquiatr Salud Ment (Engl Ed) 2019;12:9-16. [PMID: 29724678 DOI: 10.1016/j.rpsm.2018.03.004] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
39 Miller BJ, Parker CB, Rapaport MH, Buckley PF, McCall WV. Insomnia and suicidal ideation in nonaffective psychosis. Sleep 2019;42. [PMID: 30407600 DOI: 10.1093/sleep/zsy215] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 5.5] [Reference Citation Analysis]
40 Fourrier C, Sampson E, Hori H, Schubert KO, Clark S, Mills NT, Baune BT. Exploratory study of association between blood immune markers and cognitive symptom severity in major depressive disorder: Stratification by body mass index status. Brain, Behavior, and Immunity 2020;88:242-51. [DOI: 10.1016/j.bbi.2020.06.007] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
41 Muric NN, Arsenijevic NN, Borovcanin MM. Chlorpromazine as a Potential Antipsychotic Choice in COVID-19 Treatment. Front Psychiatry 2020;11:612347. [PMID: 33424669 DOI: 10.3389/fpsyt.2020.612347] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
42 Boozalis T, Devaraj S, Okusaga OO. Correlations between Body Mass Index, Plasma High-Sensitivity C-Reactive Protein and Lipids in Patients with Schizophrenia. Psychiatr Q 2019;90:101-10. [PMID: 30315442 DOI: 10.1007/s11126-018-9606-3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
43 Hori H, Kim Y. Inflammation and post‐traumatic stress disorder. Psychiatry Clin Neurosci 2019;73:143-53. [DOI: 10.1111/pcn.12820] [Cited by in Crossref: 58] [Cited by in F6Publishing: 57] [Article Influence: 19.3] [Reference Citation Analysis]
44 Palmer BW, Moore RC, Eyler LT, Pinto LL, Saks ER, Jeste DV. Avoidance of accelerated aging in schizophrenia?: Clinical and biological characterization of an exceptionally high functioning individual. Schizophr Res 2018;196:45-52. [PMID: 28801195 DOI: 10.1016/j.schres.2017.07.052] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
45 Nasib LG, Gangadin SS, Rossum IW, Boudewijns ZSRM, de Witte LD, Wilting I, Luykx J, Somers M, Veen N, van Baal C, Kahn RS, Sommer IE. The effect of prednisolone on symptom severity in schizophrenia: A placebo-controlled, randomized controlled trial. Schizophr Res 2021;230:79-86. [PMID: 33711681 DOI: 10.1016/j.schres.2021.01.024] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
46 Raison CL, Siu C, Pikalov A, Tocco M, Loebel A. C-reactive protein and response to lurasidone treatment in children and adolescents with bipolar I depression: Results from a placebo-controlled trial. Brain Behav Immun 2020;84:269-74. [PMID: 31857217 DOI: 10.1016/j.bbi.2019.12.010] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.7] [Reference Citation Analysis]
47 Pujol N, Bergé D, Mané A, Bioque M, Mezquida G, Amoretti S, Baeza I, González-pinto A, Lobo A, Cuesta MJ, Ribeiro M, Sánchez-tomico G, Pérez-solà V, Verdolini N, Vieta E, Parellada M, Roldán A, Bernardo M. The influence of modifiable cardiovascular risk factors on cognition, functioning, and inflammatory markers in first-episode psychosis: results from a 2-year follow-up study. Psychiatry Research 2022. [DOI: 10.1016/j.psychres.2022.114760] [Reference Citation Analysis]
48 Nasib LG, Sommer IE, Winter-van Rossum I, de Vries J, Gangadin SS, Oomen PP, Judge G, Blom RE, Luykx JJ, van Beveren NJM, Veen ND, Kroken RA, Johnsen EL. Prednisolone versus placebo addition in the treatment of patients with recent-onset psychotic disorder: a trial design. Trials 2020;21:492. [PMID: 32513294 DOI: 10.1186/s13063-020-04365-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
49 Çakici N, van Beveren NJM, Judge-Hundal G, Koola MM, Sommer IEC. An update on the efficacy of anti-inflammatory agents for patients with schizophrenia: a meta-analysis. Psychol Med 2019;49:2307-19. [PMID: 31439071 DOI: 10.1017/S0033291719001995] [Cited by in Crossref: 62] [Cited by in F6Publishing: 36] [Article Influence: 20.7] [Reference Citation Analysis]
50 Chumakov E, Dorofeikova M, Tsyrenova K, Petrova N. A Cross-Sectional Study on Associations Between BDNF, CRP, IL-6 and Clinical Symptoms, Cognitive and Personal Performance in Patients With Paranoid Schizophrenia. Front Psychiatry 2022;13:943869. [PMID: 35873262 DOI: 10.3389/fpsyt.2022.943869] [Reference Citation Analysis]
51 Morozova A, Zorkina Y, Pavlov K, Pavlova O, Abramova O, Ushakova V, Mudrak AV, Zozulya S, Otman I, Sarmanova Z, Klyushnik T, Reznik A, Kostyuk G, Chekhonin V. Associations of Genetic Polymorphisms and Neuroimmune Markers With Some Parameters of Frontal Lobe Dysfunction in Schizophrenia. Front Psychiatry 2021;12:655178. [PMID: 34025476 DOI: 10.3389/fpsyt.2021.655178] [Reference Citation Analysis]
52 Zamanpoor M. Schizophrenia in a genomic era: a review from the pathogenesis, genetic and environmental etiology to diagnosis and treatment insights. Psychiatr Genet 2020;30:1-9. [PMID: 31764709 DOI: 10.1097/YPG.0000000000000245] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
53 North HF, Bruggemann J, Cropley V, Swaminathan V, Sundram S, Lenroot R, Pereira AM, Zalesky A, Bousman C, Pantelis C, Weickert TW, Shannon Weickert C. Increased peripheral inflammation in schizophrenia is associated with worse cognitive performance and related cortical thickness reductions. Eur Arch Psychiatry Clin Neurosci 2021;271:595-607. [PMID: 33760971 DOI: 10.1007/s00406-021-01237-z] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 12.0] [Reference Citation Analysis]
54 Bora E. Peripheral inflammatory and neurotrophic biomarkers of cognitive impairment in schizophrenia: a meta-analysis. Psychol Med 2019;49:1971-9. [PMID: 31284882 DOI: 10.1017/S0033291719001685] [Cited by in Crossref: 49] [Cited by in F6Publishing: 39] [Article Influence: 16.3] [Reference Citation Analysis]
55 Benedetti F, Dallaspezia S, Melloni EMT, Lorenzi C, Zanardi R, Barbini B, Colombo C. Effective Antidepressant Chronotherapeutics (Sleep Deprivation and Light Therapy) Normalize the IL-1β:IL-1ra Ratio in Bipolar Depression. Front Physiol 2021;12:740686. [PMID: 34539454 DOI: 10.3389/fphys.2021.740686] [Reference Citation Analysis]
56 Severance EG, Yolken RH. Tracking a dysregulated gut-brain axis with biomarkers of the microbiome. Biomarkers in Neuropsychiatry 2020;2:100009. [DOI: 10.1016/j.bionps.2019.100009] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
57 Xiao G, He K, Chen X, Wang L, Bai X, Gao L, Zhu C, Wang K. Slow Binocular Rivalry as a Potential Endophenotype of Schizophrenia. Front Neurosci 2018;12:634. [PMID: 30258349 DOI: 10.3389/fnins.2018.00634] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
58 Hofer T, Duale N, Muusse M, Eide DM, Dahl H, Boix F, Andersen JM, Olsen AK, Myhre O. Restoration of Cognitive Performance in Mice Carrying a Deficient Allele of 8-Oxoguanine DNA Glycosylase by X-ray Irradiation. Neurotox Res 2018;33:824-36. [DOI: 10.1007/s12640-017-9833-7] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
59 Inanli I, Aydin M, Çaliskan AM, Eren I. Neutrophil/lymphocyte ratio, monocyte/lymphocyte ratio, and mean platelet volume as systemic inflammatory markers in different states of bipolar disorder. Nordic Journal of Psychiatry 2019;73:372-9. [DOI: 10.1080/08039488.2019.1640789] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
60 Hu Z, Hu M, Yuan X, Yu H, Zou J, Zhang Y, Lu Z. Verbal learning, working memory, and attention/vigilance may be candidate phenotypes of bipolar II depression in Chinese Han nationality. Acta Psychol (Amst) 2022;226:103563. [PMID: 35313178 DOI: 10.1016/j.actpsy.2022.103563] [Reference Citation Analysis]
61 Ishiguro H, Horiuchi Y, Tabata K, Liu QR, Arinami T, Onaivi ES. Cannabinoid CB2 Receptor Gene and Environmental Interaction in the Development of Psychiatric Disorders. Molecules 2018;23:E1836. [PMID: 30042304 DOI: 10.3390/molecules23081836] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
62 Barbosa IG, Ferreira RDA, Rocha NP, Mol GC, da Mata Chiaccjio Leite F, Bauer IE, Teixeira AL. Predictors of cognitive performance in bipolar disorder: The role of educational degree and inflammatory markers. Journal of Psychiatric Research 2018;106:31-7. [DOI: 10.1016/j.jpsychires.2018.09.003] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
63 Balanzá-Martínez V, Shansis FM, Tatay-Manteiga A, López-García P. Diet and Neurocognition in Mood Disorders - An Overview of the Overlooked. Curr Pharm Des 2020;26:2353-62. [PMID: 32188376 DOI: 10.2174/1381612826666200318152530] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
64 Jahrami H, Faris MA, Ghazzawi HA, Saif Z, Habib L, Shivappa N, Hébert JR. Increased Dietary Inflammatory Index Is Associated with Schizophrenia: Results of a Case-Control Study from Bahrain.Nutrients. 2019;11. [PMID: 31405205 DOI: 10.3390/nu11081867] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
65 Van Rheenen TE, Lewandowski KE, Bauer IE, Kapczinski F, Miskowiak K, Burdick KE, Balanzá-Martínez V. Current understandings of the trajectory and emerging correlates of cognitive impairment in bipolar disorder: An overview of evidence. Bipolar Disord 2020;22:13-27. [PMID: 31408230 DOI: 10.1111/bdi.12821] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 8.0] [Reference Citation Analysis]
66 Millett CE, Perez-Rodriguez M, Shanahan M, Larsen E, Yamamoto HS, Bukowski C, Fichorova R, Burdick KE. C-reactive protein is associated with cognitive performance in a large cohort of euthymic patients with bipolar disorder. Mol Psychiatry 2019. [PMID: 31740754 DOI: 10.1038/s41380-019-0591-1] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 3.7] [Reference Citation Analysis]
67 Ribeiro-santos R, de Campos-carli SM, Ferretjans R, Teixeira-carvalho A, Martins-filho OA, Teixeira AL, Salgado JV. The association of cognitive performance and IL-6 levels in schizophrenia is influenced by age and antipsychotic treatment. Nordic Journal of Psychiatry 2020;74:187-93. [DOI: 10.1080/08039488.2019.1688389] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
68 Yamada Y, Matsumoto M, Iijima K, Sumiyoshi T. Specificity and Continuity of Schizophrenia and Bipolar Disorder: Relation to Biomarkers. Curr Pharm Des 2020;26:191-200. [PMID: 31840595 DOI: 10.2174/1381612825666191216153508] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
69 Luo Y, Liu F, Natarajan R, Shukair N, Copeland P, Fan X. Salsalate as an adjunctive treatment for psychopathology and cognition in patients with schizophrenia: a pilot study. Int Clin Psychopharmacol 2018;33:88-91. [PMID: 29084087 DOI: 10.1097/YIC.0000000000000204] [Cited by in Crossref: 3] [Article Influence: 0.8] [Reference Citation Analysis]
70 Adelantado-Renau M, Beltran-Valls MR, Moliner-Urdiales D. Inflammation and Cognition in Children and Adolescents: A Call for Action. Front Pediatr 2020;8:583. [PMID: 33014950 DOI: 10.3389/fped.2020.00583] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
71 Ullah I, Awan HA, Aamir A, Diwan MN, de Filippis R, Awan S, Irfan M, Fornaro M, Ventriglio A, Vellante F, Pettorruso M, Martinotti G, Di Giannantonio M, De Berardis D. Role and Perspectives of Inflammation and C-Reactive Protein (CRP) in Psychosis: An Economic and Widespread Tool for Assessing the Disease. Int J Mol Sci 2021;22:13032. [PMID: 34884840 DOI: 10.3390/ijms222313032] [Reference Citation Analysis]
72 Giménez-Orenga K, Oltra E. Human Endogenous Retrovirus as Therapeutic Targets in Neurologic Disease. Pharmaceuticals (Basel) 2021;14:495. [PMID: 34073730 DOI: 10.3390/ph14060495] [Reference Citation Analysis]
73 Gao J, Wei Q, Pan R, Yi W, Xu Z, Duan J, Tang C, He Y, Liu X, Song S, Su H. Elevated environmental PM2.5 increases risk of schizophrenia relapse: Mediation of inflammatory cytokines. Science of The Total Environment 2021;753:142008. [DOI: 10.1016/j.scitotenv.2020.142008] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
74 Tang M, Mao X, Gong Y, Qing L, Xie J. Research Progress of C-reactive Protein Analysis. Chinese Journal of Analytical Chemistry 2020;48:1121-30. [DOI: 10.1016/s1872-2040(20)60040-8] [Cited by in Crossref: 3] [Article Influence: 1.5] [Reference Citation Analysis]
75 Chang CH, Lane HY, Liu CY, Cheng PC, Chen SJ, Lin CH. C-reactive protein is associated with severity of thought and language dysfunction in patients with schizophrenia. Neuropsychiatr Dis Treat 2019;15:2621-7. [PMID: 31571879 DOI: 10.2147/NDT.S223278] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
76 Dalkner N, Reininghaus E, Schwalsberger K, Rieger A, Hamm C, Pilz R, Lenger M, Queissner R, Falzberger VS, Platzer M, Fellendorf FT, Birner A, Bengesser SA, Weiss EM, McIntyre RS, Mangge H, Reininghaus B. C-Reactive Protein as a Possible Predictor of Trail-Making Performance in Individuals with Psychiatric Disorders. Nutrients 2020;12:E3019. [PMID: 33023087 DOI: 10.3390/nu12103019] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
77 Cattane N, Richetto J, Cattaneo A. Prenatal exposure to environmental insults and enhanced risk of developing Schizophrenia and Autism Spectrum Disorder: focus on biological pathways and epigenetic mechanisms. Neurosci Biobehav Rev 2020;117:253-78. [PMID: 29981347 DOI: 10.1016/j.neubiorev.2018.07.001] [Cited by in Crossref: 36] [Cited by in F6Publishing: 29] [Article Influence: 9.0] [Reference Citation Analysis]
78 Misiak B, Bartoli F, Carrà G, Stańczykiewicz B, Gładka A, Frydecka D, Samochowiec J, Jarosz K, Hadryś T, Miller BJ. Immune-inflammatory markers and psychosis risk: A systematic review and meta-analysis. Psychoneuroendocrinology 2021;127:105200. [PMID: 33740587 DOI: 10.1016/j.psyneuen.2021.105200] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
79 Klyushnik TP, Nikitina VB, Androsova LV, Vetlugina TP, Zozulya SA, Aksenov MM, Bokhan NA. [Inflammatory factors and immunophenotypes in adjustment disorders]. Zh Nevrol Psikhiatr Im S S Korsakova 2018;118:83-8. [PMID: 29652311 DOI: 10.17116/jnevro20181183183-88] [Reference Citation Analysis]
80 Buckley PF. Neuroinflammation and Schizophrenia. Curr Psychiatry Rep 2019;21:72. [PMID: 31267432 DOI: 10.1007/s11920-019-1050-z] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 6.0] [Reference Citation Analysis]
81 Zakowicz P, Pawlak J, Kapelski P, Wiłkość-Dębczyńska M, Szałkowska A, Twarowska-Hauser J, Rybakowski J, Skibińska M. Genetic association study reveals impact of interleukin 10 polymorphisms on cognitive functions in schizophrenia. Behav Brain Res 2022;419:113706. [PMID: 34875307 DOI: 10.1016/j.bbr.2021.113706] [Reference Citation Analysis]
82 Miller BJ, Goldsmith DR. Evaluating the Hypothesis That Schizophrenia Is an Inflammatory Disorder. Focus (Am Psychiatr Publ) 2020;18:391-401. [PMID: 33343251 DOI: 10.1176/appi.focus.20200015] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
83 Zhang L, Liu F, Zheng H, Wu R, Zhao J. Serum Interleukin-1β and tumor necrosis factor-α in first-episode drug-naive and chronic schizophrenia patients: Associated with cognitive deficits. Asian J Psychiatr 2021;58:102605. [PMID: 33636450 DOI: 10.1016/j.ajp.2021.102605] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
84 Watson AJ, Giordano A, Suckling J, Barnes TRE, Husain N, Jones PB, Krynicki CR, Lawrie SM, Lewis S, Nikkheslat N, Pariante CM, Upthegrove R, Deakin B, Dazzan P, Joyce EM. Cognitive function in early-phase schizophrenia-spectrum disorder: IQ subtypes, brain volume and immune markers. Psychol Med 2022;:1-10. [PMID: 35177144 DOI: 10.1017/S0033291721004815] [Reference Citation Analysis]
85 Morrens M, Overloop C, Coppens V, Loots E, Van Den Noortgate M, Vandenameele S, Leboyer M, De Picker L. The relationship between immune and cognitive dysfunction in mood and psychotic disorder: a systematic review and a meta-analysis. Mol Psychiatry 2022. [PMID: 35484245 DOI: 10.1038/s41380-022-01582-y] [Reference Citation Analysis]
86 Kogan S, Ospina LH, Kimhy D. Inflammation in individuals with schizophrenia - Implications for neurocognition and daily function. Brain Behav Immun 2018;74:296-9. [PMID: 30218782 DOI: 10.1016/j.bbi.2018.09.016] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
87 Fan X, Song X, Zhao M, Jarskog LF, Natarajan R, Shukair N, Freudenreich O, Henderson DC, Goff DC. The effect of adjunctive telmisartan treatment on psychopathology and cognition in patients with schizophrenia. Acta Psychiatr Scand 2017;136:465-72. [PMID: 28851055 DOI: 10.1111/acps.12799] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.4] [Reference Citation Analysis]
88 Kogan S, Ospina LH, Mittal VA, Kimhy D. The impact of inflammation on neurocognition and risk for psychosis: a critical review. Eur Arch Psychiatry Clin Neurosci 2020;270:793-802. [PMID: 31620871 DOI: 10.1007/s00406-019-01073-2] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
89 Xiu MH, Wang DM, Du XD, Chen N, Tan SP, Tan YL, Yang FD, Cho RY, Zhang XY. Interaction of BDNF and cytokines in executive dysfunction in patients with chronic schizophrenia. Psychoneuroendocrinology 2019;108:110-7. [DOI: 10.1016/j.psyneuen.2019.06.006] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
90 Morozova A, Zorkina Y, Abramova O, Pavlova O, Pavlov K, Soloveva K, Volkova M, Alekseeva P, Andryshchenko A, Kostyuk G, Gurina O, Chekhonin V. Neurobiological Highlights of Cognitive Impairment in Psychiatric Disorders. Int J Mol Sci 2022;23:1217. [PMID: 35163141 DOI: 10.3390/ijms23031217] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
91 Chen MH, Hsu JW, Huang KL, Tsai SJ, Tu PC, Bai YM. Inflammatory cytokines in and cognitive function of adolescents with first-episode schizophrenia, bipolar disorder, or major depressive disorder. CNS Spectr 2021;:1-8. [PMID: 34664544 DOI: 10.1017/S1092852921000857] [Reference Citation Analysis]
92 Strzelecki D, Urban-kowalczyk M, Wysokiński A. Serum levels of TNF-alpha in patients with chronic schizophrenia during treatment augmentation with sarcosine (results of the PULSAR study). Psychiatry Research 2018;268:447-53. [DOI: 10.1016/j.psychres.2018.08.002] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
93 Fourrier C, Singhal G, Baune BT. Neuroinflammation and cognition across psychiatric conditions. CNS Spectr 2019;24:4-15. [PMID: 30714555 DOI: 10.1017/S1092852918001499] [Cited by in Crossref: 33] [Cited by in F6Publishing: 18] [Article Influence: 11.0] [Reference Citation Analysis]
94 Myhre O, Zimmer KE, Hudecova AM, Hansen KEA, Khezri A, Berntsen HF, Berg V, Lyche JL, Mandal S, Duale N, Ropstad E. Maternal exposure to a human based mixture of persistent organic pollutants (POPs) affect gene expression related to brain function in mice offspring hippocampus. Chemosphere 2021;276:130123. [PMID: 33714876 DOI: 10.1016/j.chemosphere.2021.130123] [Cited by in F6Publishing: 3] [Reference Citation Analysis]